论文部分内容阅读
目的:探讨不同强度的3类他汀治疗对急性冠脉综合征(ACS)的疗效。方法:选取2014年1月至2014年6月茂名石化医院收治的180例ACS患者,治疗应用瑞舒伐他汀5 mg/d、瑞舒伐他汀10 mg/d、阿托伐他汀10 mg/d、阿托伐他汀20 mg/d、辛伐他汀20 mg/d或辛伐他汀40 mg/d。结果:6组治疗前血脂水平比较,差异无统计学意义(P>0.05)。3类中等强度他汀治疗均可明显降低LDL-C水平比较,差异具有统计学意义(P<0.05),6组患者不良反应和心血管事件比较,差异无统计学意义(P>0.05)。结论:中等强度的瑞舒伐他汀、阿托伐他汀、辛伐他汀均是治疗ACS的安全有效的治疗手段。
Objective: To investigate the effect of different intensity of 3 statins on acute coronary syndrome (ACS). Methods: A total of 180 ACS patients admitted from January 2014 to June 2014 in Maoming Petrochemical Hospital were enrolled in this study. Rosuvastatin 5 mg / d, rosuvastatin 10 mg / d, atorvastatin 10 mg / d , Atorvastatin 20 mg / d, simvastatin 20 mg / d or simvastatin 40 mg / d. Results: There was no significant difference in blood lipid level between the 6 groups before treatment (P> 0.05). There were no significant differences in adverse reaction and cardiovascular events between the three groups of moderate-intensity statin therapy (P <0.05), LDL-C levels (P> 0.05). Conclusions: Moderate-intensity rosuvastatin, atorvastatin and simvastatin are safe and effective treatments for ACS.